Angiotensin (1-7) vs Vladonix

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Angiotensin-(1-7) [Ang-(1-7)] is an endogenous heptapeptide hormone generated primarily through cleavage of angiotensin II by ACE2, functioning as a counter-regulatory arm of the renin-angiotensin system (RAS) by binding the Mas receptor to promote vasodilation, anti-fibrotic, anti-inflammatory, and cardioprotective effects that oppose the vasoconstrictive actions of angiotensin II. Ang-(1-7) acts through the ACE2/Mas receptor axis to reduce oxidative stress, attenuate NF-kB-mediated inflammation, and suppress TGF-beta fibrosis signaling; the ACE2/Ang-(1-7)/Mas axis has emerged as a key regulatory pathway in cardiovascular and metabolic disease, and gained renewed research attention given ACE2's role as the SARS-CoV-2 entry receptor. A Phase 1-2 randomized clinical trial of Ang-(1-7) infusion in COVID-19 ICU patients reported preliminary safety, tolerability, and dose-response data, providing the primary indexed human pharmacokinetic evidence; broader cardiovascular protective applications are supported by preclinical data but have not been established by completed Phase 3 trials. Ang-(1-7) has no FDA approval and no approved therapeutic indication in any jurisdiction; it is an endogenous peptide under active clinical investigation as a candidate for cardiovascular, metabolic, and inflammatory conditions, with emerging human safety data but an incomplete evidence base for any specific approved clinical use.

Short peptide complex penetrates cell nuclei and modulates gene expression in thymic and T-lymphocyte cells. Promotes T-cell maturation, normalizes CD4/CD8 ratios, and supports cytokine balance.

Vladonix is a Khavinson-class peptide bioregulator derived from thymus tissue, developed as part of Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore immune function in aging subjects by modulating gene expression in thymic epithelial cells and thymus-dependent lymphocyte populations. As a thymic tissue-derived bioregulator, Vladonix shares its mechanistic framework with thymalin, the better-characterized Khavinson thymus compound; both are proposed to interact with chromatin regulatory elements in thymic cells to reactivate gene expression programs that decline with immunosenescence, potentially restoring T-cell maturation and peripheral immune competence. Published research from the Khavinson group on thymus-derived short peptides, including thymalin, has demonstrated human hematopoietic stem cell differentiation activity, immune modulation in aged subjects, and class-level evidence for thymic peptide bioregulation, providing biological plausibility for this compound class. Vladonix has no FDA approval and no approved indication in any Western jurisdiction; it is the commercial thymic bioregulator product distinct from thymalin but sharing the same class evidence framework, with no independent published clinical trials specific to this formulation, and its use is confined to the Russian integrative and anti-aging medicine context.